Latest news with #revakinagene

Associated Press

Neurotech Appoints Beth Marsh as Chief Commercial Officer

CUMBERLAND, R.I.--(BUSINESS WIRE)--Apr 21, 2025-- Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced the appointment of Beth Marsh as Chief Commercial Officer, effective April 28, 2025. In this role, Beth will lead the commercial organization, including preparing for the U.S. launch of ENCELTO TM (revakinagene taroretcel-lwey), the first and only approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel). This press release features multimedia. View the full release here: Beth Marsh, Chief Commercial Officer Beth is an established commercial and strategic business executive with more than two decades of leadership experience and expertise in ophthalmology and retina. 'We are delighted to welcome Beth to Neurotech during this important time as we prepare for the availability of ENCELTO to patients this June,' said Richard Small, Chief Executive Offer. 'I am confident that Beth's expertise in launching new therapies that address unmet needs, and her extensive network and leadership in the retina community will help us quickly scale up our commercial efforts for a successful launch.' 'This is an important and transformative time to join Neurotech as the company prepares for commercialization of the first and only approved treatment for adults suffering with MacTel,' said Beth. 'Neurotech has a strong commercial organization and infrastructure in place, and I look forward to partnering with a talented team to achieve the successful launch of ENCELTO. It is an honor to join an organization focused on developing transformative therapies for chronic eye diseases.' Beth joins Neurotech from Apellis Pharmaceuticals, where she served as Vice President, North America Sales and Marketing in Ophthalmology, leading the commercial U.S. launch for SYFOVRE, the first approved treatment for geographic atrophy secondary to age-related macular degeneration. Previously, she served in commercial leadership roles at Shire / Takeda Pharmaceuticals as Global Product Strategy Lead, Ophthalmology accountable for the comprehensive commercial strategy and launch readiness for two development-stage ophthalmic programs. Beth's earlier experience included commercial and business development leadership roles at Aciex Therapeutics, Johnson & Johnson Vision Care, and Santen. She also volunteers as a non-profit leader and past president of OWL: Advancing diversity in leadership in ophthalmology. Beth earned a B.S. in Business Administration in Marketing from Miami University. ENCELTO is used to treat adults with idiopathic Macular Telangiectasia Type 2 (MacTel); a retinal disease that causes progressive vision loss. Your eye surgeon will assess your vision and review your medical history to determine if ENCELTO is the right treatment for you. IMPORTANT SAFETY INFORMATION The outpatient surgical procedure should not be performed if you are currently experiencing an active or suspected eye infection. You should not receive ENCELTO if you have a known hypersensitivity to Endothelial Serum Free Media (Endo-SFM). Before receiving ENCELTO, tell your eye surgeon about all your medical conditions, including: Post-operative care: Magnetic Resonance (MR) Conditional Information Potential side effects: Please be advised that ENCELTO and the surgical insertion has related risks such as, but not limited to, endophthalmitis (eye infection), retinal tear and detachment (retina tears and potentially separates from the eye wall resulting in vision loss), vitreous hemorrhage (bleeding within the central cavity of the eye), implant extrusion (the ENCELTO begins to work its way out of the way), suture related issues (such as suture related eye irritation or exposure of sutures), temporary or permanent loss of vision, accelerated cataract formation (clouding of the lens of the eye), and delayed dark adaptation (the ability of the eye to adjust from bright lighting conditions to dark lighting conditions). If delayed dark adaptation occurs, it is unknown for how long these symptoms will be experienced. Take the following safety precautions: It is common to experience the following symptoms following ENCELTO surgery: Call your eye surgeon for medical advice about side effects. You may report side effects to the Food and Drug Administration (FDA) at 1-800-FDA-1088. Please see full Prescribing Information and Patient Information for ENCELTO. View source version on CONTACT: Corporate Contact: Laurie Ferguson, Chief Communications Officer Phone: 401-556-8649 Email:[email protected] KEYWORD: UNITED STATES NORTH AMERICA RHODE ISLAND INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES NEUROLOGY SURGERY PHARMACEUTICAL OPTICAL BIOTECHNOLOGY SOURCE: Neurotech Pharmaceuticals, Inc. Copyright Business Wire 2025. PUB: 04/21/2025 09:20 AM/DISC: 04/21/2025 09:19 AM